Abstract We consider a fixed‐sample parallel‐group clinical trial with an interim analysis that tests Ho: μx = μy against H1: μx < μy. If we do not reject at the interim analysis, then the probability of making a type I error by rejecting Ho in favour of H2: μx > μy and the power at the final analysis are not appreciably affected by performing the interim analysis for certain relevant critical regions.